Morgan Stanley Affirms Wuxi AppTec's Annual Results Meet Expectations with "Overweight" Rating

Deep News03-24

Morgan Stanley issued a research report stating that Wuxi AppTec (02359) reported a 15.8% year-on-year increase in revenue to RMB 45.5 billion for 2025, with net profit rising 105.2% to RMB 19.2 billion. Non-IFRS adjusted net profit grew 41.3% to RMB 15 billion, aligning with expectations. Revenue from U.S. operations under continuing operations increased by 34.3% year-on-year, accounting for over 70% of the company's total revenue. Revenue from continuing operations climbed 21.4% to RMB 43.4 billion. Amid ongoing geopolitical uncertainties, the firm anticipates potential upside in the stock price driven by strong leading indicators, assigning an "Overweight" rating and listing it as a preferred stock. The target price for Wuxi AppTec (603259.SH) A-shares is set at RMB 132.

Wuxi AppTec's management has guided for an 18% to 22% growth in continuing operations revenue for 2026, equating to a revenue range of RMB 51.3 billion to RMB 53 billion. The total backlog for continuing operations reached RMB 58 billion by the end of last year, up 29% year-on-year, with orders in the oligonucleotide and peptide (TIDES) business increasing by 20%.

The report noted Wuxi AppTec's divestiture of its CRO business within the testing segment during the third quarter of last year. It is projected that the company's capital expenditure for this year will range between RMB 6.5 billion and RMB 7.5 billion, higher than the RMB 5.5 billion recorded in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182367531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 17:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182367531","market":"sh","top_or_hot":-1,"title":"Morgan Stanley Affirms Wuxi AppTec's Annual Results Meet Expectations with \"Overweight\" Rating","media":"Deep News","content":"<p>Morgan Stanley issued a research report stating that Wuxi AppTec (02359) reported a 15.8% year-on-year increase in revenue to RMB 45.5 billion for 2025, with net profit rising 105.2% to RMB 19.2 billion. Non-IFRS adjusted net profit grew 41.3% to RMB 15 billion, aligning with expectations. Revenue from U.S. operations under continuing operations increased by 34.3% year-on-year, accounting for over 70% of the company's total revenue. Revenue from continuing operations climbed 21.4% to RMB 43.4 billion. Amid ongoing geopolitical uncertainties, the firm anticipates potential upside in the stock price driven by strong leading indicators, assigning an \"Overweight\" rating and listing it as a preferred stock. The target price for Wuxi AppTec (603259.SH) A-shares is set at RMB 132.</p>\n<p>Wuxi AppTec's management has guided for an 18% to 22% growth in continuing operations revenue for 2026, equating to a revenue range of RMB 51.3 billion to RMB 53 billion. The total backlog for continuing operations reached RMB 58 billion by the end of last year, up 29% year-on-year, with orders in the oligonucleotide and peptide (TIDES) business increasing by 20%.</p>\n<p>The report noted Wuxi AppTec's divestiture of its CRO business within the testing segment during the third quarter of last year. It is projected that the company's capital expenditure for this year will range between RMB 6.5 billion and RMB 7.5 billion, higher than the RMB 5.5 billion recorded in 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Affirms Wuxi AppTec's Annual Results Meet Expectations with \"Overweight\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Affirms Wuxi AppTec's Annual Results Meet Expectations with \"Overweight\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-03-24 17:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley issued a research report stating that Wuxi AppTec (02359) reported a 15.8% year-on-year increase in revenue to RMB 45.5 billion for 2025, with net profit rising 105.2% to RMB 19.2 billion. Non-IFRS adjusted net profit grew 41.3% to RMB 15 billion, aligning with expectations. Revenue from U.S. operations under continuing operations increased by 34.3% year-on-year, accounting for over 70% of the company's total revenue. Revenue from continuing operations climbed 21.4% to RMB 43.4 billion. Amid ongoing geopolitical uncertainties, the firm anticipates potential upside in the stock price driven by strong leading indicators, assigning an \"Overweight\" rating and listing it as a preferred stock. The target price for Wuxi AppTec (603259.SH) A-shares is set at RMB 132.</p>\n<p>Wuxi AppTec's management has guided for an 18% to 22% growth in continuing operations revenue for 2026, equating to a revenue range of RMB 51.3 billion to RMB 53 billion. The total backlog for continuing operations reached RMB 58 billion by the end of last year, up 29% year-on-year, with orders in the oligonucleotide and peptide (TIDES) business increasing by 20%.</p>\n<p>The report noted Wuxi AppTec's divestiture of its CRO business within the testing segment during the third quarter of last year. It is projected that the company's capital expenditure for this year will range between RMB 6.5 billion and RMB 7.5 billion, higher than the RMB 5.5 billion recorded in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1182367531","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182367531","pubTimestamp":1774345239,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Morgan Stanley issued a research report stating that Wuxi AppTec (02359) reported a 15.8% year-on-year increase in revenue to RMB 45.5 billion for 2025, with net profit rising 105.2% to RMB 19.2...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","BK0216":"研究试验","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","BK1141":"生命科学工具和服务","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","BK1576":"医药外包概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","02359":"药明康德","BK1583":"高瓴概念"},"translate_title":"大摩肯定药明康德全年业绩符合预期给予“跑赢大盘”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":1},"content_text":"Morgan Stanley issued a research report stating that Wuxi AppTec (02359) reported a 15.8% year-on-year increase in revenue to RMB 45.5 billion for 2025, with net profit rising 105.2% to RMB 19.2 billion. Non-IFRS adjusted net profit grew 41.3% to RMB 15 billion, aligning with expectations. Revenue from U.S. operations under continuing operations increased by 34.3% year-on-year, accounting for over 70% of the company's total revenue. Revenue from continuing operations climbed 21.4% to RMB 43.4 billion. Amid ongoing geopolitical uncertainties, the firm anticipates potential upside in the stock price driven by strong leading indicators, assigning an \"Overweight\" rating and listing it as a preferred stock. The target price for Wuxi AppTec (603259.SH) A-shares is set at RMB 132.\nWuxi AppTec's management has guided for an 18% to 22% growth in continuing operations revenue for 2026, equating to a revenue range of RMB 51.3 billion to RMB 53 billion. The total backlog for continuing operations reached RMB 58 billion by the end of last year, up 29% year-on-year, with orders in the oligonucleotide and peptide (TIDES) business increasing by 20%.\nThe report noted Wuxi AppTec's divestiture of its CRO business within the testing segment during the third quarter of last year. It is projected that the company's capital expenditure for this year will range between RMB 6.5 billion and RMB 7.5 billion, higher than the RMB 5.5 billion recorded in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182367531","isCrawlerRequest":true}